Laura Kristin Newby, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail Duke Box 3213, Durham, NC 27710
Phone (919) 668-8805
Email address newby001@mc.duke.edu

Research Description

General Focus: Clinical investigation the process and treatment of acute and chronic coronary artery disease and systems issues for delivery of care to patients with these illnesses. Particular interests include management of patients with chest pain and unstable angina, evaluation of the use of biochemical markers other than CK-MB for diagnosis and risk stratification in these patients, issues related to coronary artery disease in women, and systems issues regarding optimizing the process of delivery of care to patients with acute and chronic coronary artery disease. Finally, I have a strong interest in defining the genetic contribution to development of coronary artery disease.

Key words: coronary artery disease acute myocardial infarction unstable angina chest pain women biochemical markers risk stratification genetics

In Their Words

Education and Training

  • Fellow in Cardiology, Medicine, Duke University, 1990 - 1993
  • Medical Resident, Medicine, Duke University, 1987 - 1990
  • M.D., Indiana University at Indianapolis, 1987

Publications

Kelsey, Michelle D., and L Kristin Newby. “In patients at high CV risk receiving simvastatin, the Myopathy Risk Score predicted statin-related myopathy.” Ann Intern Med 173, no. 12 (December 15, 2020): JC71. https://doi.org/10.7326/ACPJ202012150-071.

PMID
33316194
Full Text

Douglas, Teresa D., L Kristin Newby, Julie Eckstrand, Douglas Wixted, and Rani H. Singh. “Lipid changes in the metabolome of a single case study with maple syrup urine disease (MSUD) after five days of improved diet adherence of controlled branched-chain amino acids (BCAA).” Mol Genet Metab Rep 25 (December 2020): 100651. https://doi.org/10.1016/j.ymgmr.2020.100651.

PMID
33088714
Full Text

Kelsey, Michelle D., and L Kristin Newby. “In older patients with NSTE-ACS, clopidogrel safely reduced bleeding compared with ticagrelor at 1 year.” Ann Intern Med 173, no. 6 (September 15, 2020): JC28. https://doi.org/10.7326/ACPJ202009150-028.

PMID
32926825
Full Text

Prabhakaran, Dorairaj, Pablo Perel, Ambuj Roy, Kavita Singh, Lana Raspail, José Rocha Faria-Neto, Samuel S. Gidding, et al. “Correction: Management of Cardiovascular Disease Patients With Confirmed or Suspected COVID-19 in Limited Resource Settings.” Glob Heart 15, no. 1 (August 7, 2020): 54. https://doi.org/10.5334/gh.885.

PMID
32925986
Full Text

Koshizaka, Masaya, Ko Ishikawa, Ryoichi Ishibashi, Yoshiro Maezawa, Kenichi Sakamoto, Daigaku Uchida, Susumu Nakamura, et al. “Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study).” J Diabetes Investig, July 4, 2020. https://doi.org/10.1111/jdi.13340.

PMID
32623839
Full Text

Prabhakaran, Dorairaj, Pablo Perel, Ambuj Roy, Kavita Singh, Lana Raspail, José Rocha Faria-Neto, Samuel S. Gidding, et al. “Management of Cardiovascular Disease Patients With Confirmed or Suspected COVID-19 in Limited Resource Settings.” Glob Heart 15, no. 1 (July 1, 2020): 44. https://doi.org/10.5334/gh.823.

PMID
32923338
Full Text

Loungani, Rahul S., Michael R. Rehorn, L Kristin Newby, Jason N. Katz, Igor Klem, Robert J. Mentz, W Schuyler Jones, et al. “A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response.” Am Heart J 225 (July 2020): 3–9. https://doi.org/10.1016/j.ahj.2020.04.024.

PMID
32417526
Full Text

Penning, Melody L., Collette Blach, Anita Walden, Pei Wang, Katrina M. Donovan, Maryam Y. Garza, Zhan Wang, et al. “Near Real Time EHR Data Utilization in a Clinical Study.” Stud Health Technol Inform 270 (June 16, 2020): 337–41. https://doi.org/10.3233/SHTI200178.

PMID
32570402
Full Text

Sen, Sounok, and L Kristin Newby. “In HF with LVEF ≤ 42.5%, sacubitril-valsartan vs RAS inhibitors reduced a composite of CV death or HF hospitalization.” Ann Intern Med 172, no. 12 (June 16, 2020): JC65. https://doi.org/10.7326/ACPJ202006160-065.

PMID
32539517
Full Text

Lowenstern, Angela, Richa Gupta, Maulikkumar Patel, Thomas Granger, Douglas Wixted, Karen Alexander, Deepak Kumar, and L Kristin Newby. “MOLECULAR MARKERS OF SURVIVAL TO ADVANCED AGE WITH CARDIOVASCULAR DISEASE: RESULTS FROM THE MURDOCK STUDY.” In Journal of the American College of Cardiology, 75:147–147. ELSEVIER SCIENCE INC, 2020.

Scholars@Duke

Pages